These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 19437097)

  • 41. Is there a common SUV threshold in oncological FDG PET/CT, at least for some common indications? A retrospective study.
    Nguyen NC; Kaushik A; Wolverson MK; Osman MM
    Acta Oncol; 2011 Jun; 50(5):670-7. PubMed ID: 21247262
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The diagnostic role of dual-phase (18)F-FDG PET/CT in the characterization of solitary pulmonary nodules.
    Demir Y; Polack BD; Karaman C; Ozdoğan O; Sürücü E; Ayhan S; Akkoçlu A; Ozdemir N
    Nucl Med Commun; 2014 Mar; 35(3):260-7. PubMed ID: 24468852
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual-time-point F-18 FDG PET/CT imaging for differentiating the lymph nodes between malignant lymphoma and benign lesions.
    Nakayama M; Okizaki A; Ishitoya S; Sakaguchi M; Sato J; Aburano T
    Ann Nucl Med; 2013 Feb; 27(2):163-9. PubMed ID: 23188388
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A stepwise approach using metabolic volume and SUVmax to differentiate malignancy and dysplasia from benign colonic uptakes on 18F-FDG PET/CT.
    Oh JR; Min JJ; Song HC; Chong A; Kim GE; Choi C; Seo JH; Bom HS
    Clin Nucl Med; 2012 Jun; 37(6):e134-40. PubMed ID: 22614211
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FDG-PET/CT for the early prediction of histopathological complete response to neoadjuvant chemotherapy in breast cancer patients: initial results.
    Buchbender C; Kuemmel S; Hoffmann O; Stahl AR; Kimmig R; Otterbach F; Ladd S; Koeninger A; Forsting M; Bockisch A; Antoch G; Heusner TA
    Acta Radiol; 2012 Jul; 53(6):628-36. PubMed ID: 22761341
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive significance of standardized uptake value parameters of FDG-PET in patients with non-small cell lung carcinoma.
    Duan XY; Wang W; Li M; Li Y; Guo YM
    Braz J Med Biol Res; 2015 Mar; 48(3):267-72. PubMed ID: 25651460
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Accuracy of PET/CT in characterization of solitary pulmonary lesions.
    Kim SK; Allen-Auerbach M; Goldin J; Fueger BJ; Dahlbom M; Brown M; Czernin J; Schiepers C
    J Nucl Med; 2007 Feb; 48(2):214-20. PubMed ID: 17268017
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Focal uptake of fluorodeoxyglucose by the thyroid in patients undergoing initial disease staging with combined PET/CT for non-small cell lung cancer.
    Yi JG; Marom EM; Munden RF; Truong MT; Macapinlac HA; Gladish GW; Sabloff BS; Podoloff DA
    Radiology; 2005 Jul; 236(1):271-5. PubMed ID: 15987980
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PET/CT features discriminate risk of metastasis among single-bone FDG lesions detected in newly diagnosed non-small-cell lung cancer patients.
    Lim CH; Ahn TR; Moon SH; Cho YS; Choi JY; Kim BT; Lee KH
    Eur Radiol; 2019 Apr; 29(4):1903-1911. PubMed ID: 30315418
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Differentiation of malignant and benign superficial lymph nodes by dual time point 18F-FDG PET].
    Su MG; Fan QP; Tian Y; Li FL; Yang XC; Li L; Fan CZ; Tian R
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 May; 40(3):517-20. PubMed ID: 19627018
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Narrow time-window dual-point 18F-FDG PET for the diagnosis of thoracic malignancy.
    Conrad GR; Sinha P
    Nucl Med Commun; 2003 Nov; 24(11):1129-37. PubMed ID: 14569166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparing the Diagnostic Potential of 68Ga-Alfatide II and 18F-FDG in Differentiating Between Non-Small Cell Lung Cancer and Tuberculosis.
    Kang F; Wang S; Tian F; Zhao M; Zhang M; Wang Z; Li G; Liu C; Yang W; Li X; Wang J
    J Nucl Med; 2016 May; 57(5):672-7. PubMed ID: 26719378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An exceptional group of non-small cell lung cancer difficult to diagnose: Evaluation of lipid-poor adrenal lesions.
    Simsek FS; Arslan M; Dag Y
    Bosn J Basic Med Sci; 2019 May; 19(2):195-200. PubMed ID: 30997878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Accuracy of early and delayed FDG PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: a preliminary study on 30 patients.
    Schillaci O; Travascio L; Bolacchi F; Calabria F; Bruni C; Cicciò C; Guazzaroni M; Orlacchio A; Simonetti G
    Radiol Med; 2009 Sep; 114(6):890-906. PubMed ID: 19579015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. 18F-FDG PET/CT qualitative and quantitative evaluation in neurofibromatosis type 1 patients for detection of malignant transformation: comparison of early to delayed imaging with and without liver activity normalization.
    Chirindel A; Chaudhry M; Blakeley JO; Wahl R
    J Nucl Med; 2015 Mar; 56(3):379-85. PubMed ID: 25655626
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Integrated FDG-PET/CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study.
    Tournoy KG; Maddens S; Gosselin R; Van Maele G; van Meerbeeck JP; Kelles A
    Thorax; 2007 Aug; 62(8):696-701. PubMed ID: 17687098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up.
    Konings R; van Gool MH; Bard MP; Zwijnenburg A; Titulaer BM; Aukema TS; Valdés Olmos RA; Sikorska K; Klomp HM; Rijna H
    Ann Nucl Med; 2016 Jun; 30(5):362-8. PubMed ID: 26961089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does dual-time-point
    Wu B; Zhao Y; Zhang Y; Tan H; Shi H
    Hell J Nucl Med; 2017; 20(1):79-82. PubMed ID: 28315913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Correlation of ¹⁸F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer.
    Han B; Lin S; Yu LJ; Wang RZ; Wang YY
    Nucl Med Commun; 2009 Nov; 30(11):831-7. PubMed ID: 19734817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.